Based on electrical biochips made in Si-technology cost effective portable devices have been constructed for field applications and point of care diagnosis. These miniaturized amperometric biosensor devices enable the evaluation of biomolecular interactions by measuring the redox recycling of ELISA products, as well as the electrical monitoring of metabolites. The highly sensitive redox recycling is facilitated by interdigitated ultramicroelectrodes of high spatial resolution. The application of these electrical biochips as DNA microarrays for the molecular diagnosis of viral infections demonstrates the measurement procedure. Self-assembling of capture oligonucleotides via thiol-gold coupling has been used to construct the DNA interface on-chip. Another application for this electrical detection principle is continuous measuring with bead-based biosensors. Here, paramagnetic nanoparticles are used as carriers of the bioanalytical interface in ELISA format. A Si-micromachined glucose sensor for continuous monitoring in interstitial fluid ex vivo shows the flexibility of the electrical platform. Here the novel approach is a pore membrane in micrometer-dimensions acting as a diffusion barrier. The electrochemical detection takes place in a cavity containing glucose oxidase and a Pt-electrode surface. The common hydrogen peroxide detection, together with Si technology, enable precise differential measurements using a second cavity.

No abstract

No abstract

For a diabetes mellitus patient, tight control of glucose level is essential. Results are reported of an investigation of the suitability of existing wearable continuous insulin infusors controlled and adjusted by a control algorithm using continuous glucose measurements as input to perform the functionality of an artificial pancreas. Special attention was given to the development of a continuous glucose monitor and to evaluate which quality of input data is necessary for the control algorithm. In clinical trials, it was found that for patients in a controlled environment an autonomously regulating control algorithm leads to an improved adjustment of patient glucose values and less overall insulin infusion as compared with the best fixed preprogrammed insulin infusion profiles of standard pump therapy. For the limited number of cases studied here, functionality of the control algorithm could tolerate some delay between the actual glucose values in the patient interstitial fluid and the algorithm input of up to 30 min. A quasicontinuous glucose measurement delivering actual glucose values every 5-10 min seems to be suited to control an artificial pancreas.

No abstract